Vertex doses first patient with next type 1 diabetes cell therapy program, while padding its coffers with strong Q2
Vertex has dosed the first type 1 diabetes patient with its next cell therapy program, the Boston biotech said Tuesday as part of its quarterly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
